Developer docs
API playgroundTry for free, no card

Search company profiles

Perfuse Therapeutics

Full company profile

uuid0000rwp

Namestring
Perfuse Therapeutics
Legal namestring
Perfuse Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing therapies that target pathologic endothelin signaling in ischemia-induced ocular diseases. Its lead asset, PER-001, is a first-in-class small molecule endothelin receptor antagonist formulated in a proprietary 4 mm bio-erodible cylindrical intravitreal implant administered via a single-use 25-gauge applicator, engineered to release drug over a six-month dosing interval — versus more frequent injections required by competing sustained-release ocular products. The company's therapeutic hypothesis is that blocking the endothelin pathway improves ocular blood flow and prevents retinal cell death in diseases such as glaucoma and diabetic retinopathy, with disclosed pipeline extensions into dry AMD/geographic atrophy, retinal vein occlusion, and retinopathy of prematurity (the last via a topical formulation).

Perfuse was founded by Sevgi Gurkan, MD and operated from South San Francisco, CA (corporate headquarters) with R&D facilities in Durham, NC, employing 1–10 people throughout its independent existence. The company is pre-revenue and generated no commercial sales prior to its acquisition; its underlying technology platform — a sustained-release, bio-erodible intravitreal implant supporting twice-yearly dosing — is the foundation of its value proposition and is protected by what the company describes as a strong and wide-ranging intellectual property portfolio across drug candidates, the delivery platform, and methods of treatment. Pre-acquisition financing was provided by a syndicate of ophthalmology-focused venture capital firms including OrbiMed, Access Biotechnology, Hatteras Venture Partners, and Lilly Asia Ventures, with disclosed funding of approximately $9.0 million in a single 2020 round.

On May 6, 2026, Bayer AG announced an agreement to fully acquire Perfuse for up to $2.45 billion ($300 million upfront plus development, regulatory, and commercial milestone payments), and the acquisition closed on June 17, 2026. Post-closing, Perfuse was fully integrated into Bayer's pharmaceutical operations, with PER-001's commercial value to be realized through Bayer's existing ophthalmology sales infrastructure. As an independent revenue-generating entity, Perfuse had no commercial customers; its single value-realization event was the Bayer acquisition.

Short descriptiontext

Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing PER-001, a first-in-class endothelin receptor antagonist delivered via a 6-month sustained-release intravitreal implant to treat ischemia-induced ocular diseases such as glaucoma and diabetic retinopathy. It was acquired by Bayer AG in June 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ophthalmic therapeutics, ocular drug delivery, intravitreal implants, retinal disease treatment, endothelin receptor antagonists
Industry3 codes
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Acquisition Value
TypeLicensing Royalties
Description

Perfuse Therapeutics is a clinical-stage biopharmaceutical company that had not yet commercialized any product. Its sole value-generating event is its acquisition by Bayer, valued at up to $2.45 billion (comprising $300 million upfront and up to $2.15 billion in development, regulatory, and commercial milestone payments). Future revenue will be derived from commercialization of PER-001 by Bayer.

citybiz.co
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PER-001
Description

Lead therapeutic candidate: a first-in-class small molecule endothelin receptor antagonist delivered in a sustained-release, bio-erodible intravitreal implant designed for six-month dosing; being developed for glaucoma, diabetic retinopathy, dry AMD/geographic atrophy, and retinal vein occlusion.

perfusetherapeutics.com
Core offering1 text field

Perfuse Therapeutics develops PER-001, a first-in-class small molecule endothelin receptor antagonist formulated in a proprietary sustained-release, bio-erodible intravitreal implant administered via a single-use 25-gauge applicator and designed for 6-month dosing intervals. PER-001 is being advanced through clinical development for ischemia-induced ocular diseases, with lead indications in glaucoma and diabetic retinopathy and pipeline expansion into dry AMD/geographic atrophy, retinal vein occlusion, and retinopathy of prematurity.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Perfuse Therapeutics is a single-asset-focused clinical-stage biopharmaceutical company built around its proprietary sustained-release drug delivery platform, with PER-001 (Intravitreal Sustained Release Implant) as the lead first-in-class small molecule endothelin receptor antagonist candidate administered via a 4 mm bio-erodible cylindrical implant every six months for glaucoma, diabetic retinopathy, dry AMD/geographic atrophy, and retinal vein occlusion, complemented by an early-stage PER-001 topical formulation in development for Retinopathy of Prematurity. As of 2026, Perfuse has been fully acquired by Bayer and is integrated into Bayer's pharmaceutical ophthalmology pipeline.

Product and service2 records
1PER-001 Intravitreal Sustained Release Implant
CategoryLead Therapeutic Candidate (Ophthalmic Biologic / Small Molecule Intravitreal Implant)
Description

First-in-class small molecule endothelin receptor antagonist formulated in a 4 mm bio-erodible cylindrical intravitreal implant, administered via a single-use 25-gauge applicator into the vitreous cavity, designed to provide sustained release over 6 months for the treatment of glaucoma, diabetic retinopathy, dry AMD/geographic atrophy, and retinal vein occlusion. PER-001 is an investigational therapy in Phase II clinical development, intended for adult patients with ischemia-induced ocular diseases; it has not yet been approved by the FDA.

2PER-001 Topical Formulation
CategoryPipeline Candidate (Topical Ophthalmic Therapeutic)
Description

Topical formulation of the PER-001 endothelin receptor antagonist in early pipeline development, intended to expand the PER-001 franchise beyond intravitreal delivery to address Retinopathy of Prematurity in neonatal patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ophthalmology company developing sustained-release intravitreal drug delivery (including bioerodible hydrogel implants for retinal diseases) — directly comparable platform mechanism and target indications to Perfuse's PER-001 implant.

TypeBroad incumbent
Description

Developer and commercializer of EYLEA (aflibercept), the standard anti-VEGF therapy for diabetic retinopathy, wet AMD, and retinal vein occlusion — direct comparator in PER-001's DR/RVO indications and Bayer's existing partnership peer.

TypeBroad incumbent
Description

Markets Lucentis, faricimab (Vabysmo), and Susvimo (the only approved sustained-release ocular implant for wet AMD) — directly comparable both as a retinal disease incumbent and as the only other company with an approved SR ocular implant platform.

TypeDirect peer
Description

Was a clinical-to-commercial glaucoma specialist (Rhopressa/Roclatan) acquired by Alcon in 2022; comparable as a venture-backed glaucoma therapeutics company with novel mechanism targeting IOP and disease modification.

TypeDirect peer
Description

Develops SYFOVRE for geographic atrophy (dry AMD) and EMPAVELI; directly comparable as a clinical-stage ophthalmology biotech that advanced a novel mechanism for an ischemia/AMD-adjacent indication and executed pivotal trials.

TypeDirect peer
Description

Clinical-stage biopharma developing novel therapeutics for retinal diseases including diabetic retinopathy and AMD; comparable in stage, ophthalmology focus, and novel-mechanism approach to PER-001.

TypeDirect peer
Description

Late clinical-stage ophthalmology company developing Nyxol for glaucoma and presbyopia; comparable as a venture-backed, single-mechanism-focused glaucoma therapeutics company.

TypeEmerging player
Description

Clinical-stage gene therapy company developing single-administration intravitreal treatments (ixoberogene soroparvovec) for wet AMD and DR — overlaps with Perfuse on sustained-effect ocular drug delivery in retinal disease.

TypeDirect peer
Description

Developed Izervay for geographic atrophy and was acquired by Astellas in 2023 for ~$5.9B — comparable as a clinical-stage ophthalmology biotech focused on novel-mechanism treatment of a retinal indication, and as a recent premium M&A comparable.

TypeBroad incumbent
Description

Established global ophthalmology franchise with branded pharmaceuticals (e.g., Vyzulta for glaucoma, BEOVU) and surgical/consumer eye health; relevant comparable as a broad incumbent Bayer competes with across ophthalmology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Perfuse Therapeutics

Ophthalmic Biopharmaceuticalsperfusetherapeutics.com

Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing PER-001, a first-in-class endothelin receptor antagonist delivered via a 6-month sustained-release intravitreal implant to treat ischemia-induced ocular diseases such as glaucoma and diabetic retinopathy. It was acquired by Bayer AG in June 2026.

What Perfuse Therapeutics does

Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing therapies that target pathologic endothelin signaling in ischemia-induced ocular diseases. Its lead asset, PER-001, is a first-in-class small molecule endothelin receptor antagonist formulated in a proprietary 4 mm bio-erodible cylindrical intravitreal implant administered via a single-use 25-gauge applicator, engineered to release drug over a six-month dosing interval — versus more frequent injections required by competing sustained-release ocular products. The company's therapeutic hypothesis is that blocking the endothelin pathway improves ocular blood flow and prevents retinal cell death in diseases such as glaucoma and diabetic retinopathy, with disclosed pipeline extensions into dry AMD/geographic atrophy, retinal vein occlusion, and retinopathy of prematurity (the last via a topical formulation).

Perfuse was founded by Sevgi Gurkan, MD and operated from South San Francisco, CA (corporate headquarters) with R&D facilities in Durham, NC, employing 1–10 people throughout its independent existence. The company is pre-revenue and generated no commercial sales prior to its acquisition; its underlying technology platform — a sustained-release, bio-erodible intravitreal implant supporting twice-yearly dosing — is the foundation of its value proposition and is protected by what the company describes as a strong and wide-ranging intellectual property portfolio across drug candidates, the delivery platform, and methods of treatment. Pre-acquisition financing was provided by a syndicate of ophthalmology-focused venture capital firms including OrbiMed, Access Biotechnology, Hatteras Venture Partners, and Lilly Asia Ventures, with disclosed funding of approximately $9.0 million in a single 2020 round.

On May 6, 2026, Bayer AG announced an agreement to fully acquire Perfuse for up to $2.45 billion ($300 million upfront plus development, regulatory, and commercial milestone payments), and the acquisition closed on June 17, 2026. Post-closing, Perfuse was fully integrated into Bayer's pharmaceutical operations, with PER-001's commercial value to be realized through Bayer's existing ophthalmology sales infrastructure. As an independent revenue-generating entity, Perfuse had no commercial customers; its single value-realization event was the Bayer acquisition.

Perfuse Therapeutics firmographics

Firmographics
Name
Perfuse Therapeutics
Legal name
Perfuse Therapeutics, Inc.
Website
https://perfusetherapeutics.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
1–10 employees
Short description
Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing PER-001, a first-in-class endothelin receptor antagonist delivered via a 6-month sustained-release intravitreal implant to treat ischemia-induced ocular diseases such as glaucoma and diabetic retinopathy. It was acquired by Bayer AG in June 2026.
Ownership category
akta.pro rank

Where Perfuse Therapeutics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Perfuse Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Pre-revenue / Acquisition Value: Perfuse Therapeutics is a clinical-stage biopharmaceutical company that had not yet commercialized any product. Its sole value-generating event is its acquisition by Bayer, valued at up to $2.45 billion (comprising $300 million upfront and up to $2.15 billion in development, regulatory, and commercial milestone payments). Future revenue will be derived from commercialization of PER-001 by Bayer.

Go-to-market motion1 record

Perfuse Therapeutics product offering

Product offering

Core offering

Perfuse Therapeutics develops PER-001, a first-in-class small molecule endothelin receptor antagonist formulated in a proprietary sustained-release, bio-erodible intravitreal implant administered via a single-use 25-gauge applicator and designed for 6-month dosing intervals. PER-001 is being advanced through clinical development for ischemia-induced ocular diseases, with lead indications in glaucoma and diabetic retinopathy and pipeline expansion into dry AMD/geographic atrophy, retinal vein occlusion, and retinopathy of prematurity.

Product overview

Perfuse Therapeutics is a single-asset-focused clinical-stage biopharmaceutical company built around its proprietary sustained-release drug delivery platform, with PER-001 (Intravitreal Sustained Release Implant) as the lead first-in-class small molecule endothelin receptor antagonist candidate administered via a 4 mm bio-erodible cylindrical implant every six months for glaucoma, diabetic retinopathy, dry AMD/geographic atrophy, and retinal vein occlusion, complemented by an early-stage PER-001 topical formulation in development for Retinopathy of Prematurity. As of 2026, Perfuse has been fully acquired by Bayer and is integrated into Bayer's pharmaceutical ophthalmology pipeline.

Differentiator

Problem solved

Functional benefit

Brands

  • PER-001: Lead therapeutic candidate: a first-in-class small molecule endothelin receptor antagonist delivered in a sustained-release, bio-erodible intravitreal implant designed for six-month dosing; being developed for glaucoma, diabetic retinopathy, dry AMD/geographic atrophy, and retinal vein occlusion.

Products and services

  • PER-001 Intravitreal Sustained Release Implant First-in-class small molecule endothelin receptor antagonist formulated in a 4 mm bio-erodible cylindrical intravitreal implant, administered via a single-use 25-gauge applicator into the vitreous cavity, designed to provide sustained release over 6 months for the treatment of glaucoma, diabetic retinopathy, dry AMD/geographic atrophy, and retinal vein occlusion. PER-001 is an investigational therapy in Phase II clinical development, intended for adult patients with ischemia-induced ocular diseases; it has not yet been approved by the FDA.
  • PER-001 Topical Formulation Topical formulation of the PER-001 endothelin receptor antagonist in early pipeline development, intended to expand the PER-001 franchise beyond intravitreal delivery to address Retinopathy of Prematurity in neonatal patients.

Companies that use Perfuse Therapeutics

Customer profile

Ideal customer profiles2 records

Perfuse Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Perfuse Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Perfuse Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ocular Therapeutix: Clinical-stage ophthalmology company developing sustained-release intravitreal drug delivery (including bioerodible hydrogel implants for retinal diseases) — directly comparable platform mechanism and target indications to Perfuse's PER-001 implant.
  • Aerie Pharmaceuticals: Was a clinical-to-commercial glaucoma specialist (Rhopressa/Roclatan) acquired by Alcon in 2022; comparable as a venture-backed glaucoma therapeutics company with novel mechanism targeting IOP and disease modification.
  • Apellis Pharmaceuticals: Develops SYFOVRE for geographic atrophy (dry AMD) and EMPAVELI; directly comparable as a clinical-stage ophthalmology biotech that advanced a novel mechanism for an ischemia/AMD-adjacent indication and executed pivotal trials.
  • Kodiak Sciences: Clinical-stage biopharma developing novel therapeutics for retinal diseases including diabetic retinopathy and AMD; comparable in stage, ophthalmology focus, and novel-mechanism approach to PER-001.
  • Ocuphire Pharma: Late clinical-stage ophthalmology company developing Nyxol for glaucoma and presbyopia; comparable as a venture-backed, single-mechanism-focused glaucoma therapeutics company.
  • Iveric Bio: Developed Izervay for geographic atrophy and was acquired by Astellas in 2023 for ~$5.9B — comparable as a clinical-stage ophthalmology biotech focused on novel-mechanism treatment of a retinal indication, and as a recent premium M&A comparable.

Broad incumbents

  • Regeneron Pharmaceuticals: Developer and commercializer of EYLEA (aflibercept), the standard anti-VEGF therapy for diabetic retinopathy, wet AMD, and retinal vein occlusion — direct comparator in PER-001's DR/RVO indications and Bayer's existing partnership peer.
  • Genentech (Roche): Markets Lucentis, faricimab (Vabysmo), and Susvimo (the only approved sustained-release ocular implant for wet AMD) — directly comparable both as a retinal disease incumbent and as the only other company with an approved SR ocular implant platform.
  • Bausch + Lomb: Established global ophthalmology franchise with branded pharmaceuticals (e.g., Vyzulta for glaucoma, BEOVU) and surgical/consumer eye health; relevant comparable as a broad incumbent Bayer competes with across ophthalmology.

Emerging players

  • Adverum Biotechnologies: Clinical-stage gene therapy company developing single-administration intravitreal treatments (ixoberogene soroparvovec) for wet AMD and DR — overlaps with Perfuse on sustained-effect ocular drug delivery in retinal disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

Perfuse Therapeutics social profiles

Digital presence

Perfuse Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Perfuse Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Perfuse Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Perfuse Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perfuse Therapeutics

What does Perfuse Therapeutics do?

Perfuse Therapeutics develops PER-001, a first-in-class small molecule endothelin receptor antagonist formulated in a proprietary sustained-release, bio-erodible intravitreal implant administered via a single-use 25-gauge applicator and designed for 6-month dosing intervals. PER-001 is being advanced through clinical development for ischemia-induced ocular diseases, with lead indications in glaucoma and diabetic retinopathy and pipeline expansion into dry AMD/geographic atrophy, retinal vein occlusion, and retinopathy of prematurity.

Is Perfuse Therapeutics a public or private company?

Perfuse Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Perfuse Therapeutics founded?

Perfuse Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Perfuse Therapeutics based?

Perfuse Therapeutics is headquartered in San Francisco, United States, in the North America region.

How does Perfuse Therapeutics make money?

One revenue line is on record: pre-revenue / Acquisition Value.

Who are Perfuse Therapeutics's main competitors?

Direct peers on record are Ocular Therapeutix, Aerie Pharmaceuticals, Apellis Pharmaceuticals, Kodiak Sciences, Ocuphire Pharma and Iveric Bio. Broad incumbents are Regeneron Pharmaceuticals, Genentech (Roche) and Bausch + Lomb. Adverum Biotechnologies is listed as an emerging player.

Does Perfuse Therapeutics have an API?

No public API is recorded for Perfuse Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumBayer names Christoph Koenen as its new CMOBayer appointed Dr Christoph Koenen as its new chief medical officer, replacing Mike Devoy, who left in February. Koenen, who has been at Bayer since 2022, will lead medical and scientific strategies across the group. His role supports Bayer's five-year plan to expand its pharmaceutical operating margin toward 30% by 2030.Digital Health NewsBayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 BnBayer is set to acquire Perfuse Therapeutics in a deal valued at up to $2.45 billion, including an upfront payment and milestone-based payments. The acquisition aims to expand Bayer’s ophthalmology portfolio with the experimental drug PER-001, which is in Phase II development for eye diseases.Ophthalmology TimesBayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilitiesBayer has completed its acquisition of Perfuse Therapeutics and simultaneously entered a drug discovery collaboration with Iambic Therapeutics, marking a dual-track expansion of its ophthalmology and AI-driven pharmaceutical research capabilities. The total deal value reaches up to $2.45 billion USD, comprising a $300 million upfront payment and success-based milestone payments, with Perfuse's lead asset PER-001—a first-in-class sustained-release endothelin receptor antagonist—advancing to pivotal Phase 2b/3 trials for glaucoma and diabetic retinopathy. The Iambic partnership will leverage AI technologies Enchant and NeuralPLexer to accelerate identification of novel small molecule candidates across Bayer's R&D portfolio, with the goal of compressing optimization timelines in drug discovery.Pulse 2.0Bayer Completes Acquisition Of Perfuse Therapeutics In Deal Worth Up To $2.45 BillionBayer completed its acquisition of Perfuse Therapeutics, paying $300 million upfront with total potential value up to $2.45 billion. The deal gives Bayer full rights to PER-001, a Phase II intravitreal implant for glaucoma and diabetic retinopathy. The acquisition strengthens Bayer's ophthalmology pipeline.citybizBayer Completes Perfuse Therapeutics Acquisition to Strengthen Ophthalmology PipelineBayer has completed its acquisition of Perfuse Therapeutics, gaining full rights to PER-001, a first-in-class intravitreal implant in Phase II clinical development for glaucoma and diabetic retinopathy. The transaction was valued at up to $2.45 billion, including $300 million upfront and additional success-based milestone payments. The acquisition strengthens Bayer's ophthalmology pipeline and reflects continued interest from large pharmaceutical companies in specialty ophthalmology assets.AijournBayer Completes Acquisition of Perfuse TherapeuticsBayer has completed its acquisition of Perfuse Therapeutics, paying an upfront amount of USD 300 million with a total potential deal value of up to USD 2.45 billion including success-based milestone payments. The acquisition gives Bayer full rights to PER-001, a first-in-class sustained-release endothelin receptor antagonist currently in Phase II clinical trials for treating Glaucoma and Diabetic Retinopathy. The deal strengthens Bayer's pharmaceutical pipeline and strategically aligns with its existing ophthalmology expertise.YahooBayer Completes Acquisition of Perfuse TherapeuticsBayer completed its acquisition of Perfuse Therapeutics, integrating the company fully. The deal includes a $300 million upfront payment and potential milestone payments up to $2.45 billion. Bayer now holds full rights to PER-001, a Phase II drug for glaucoma and diabetic retinopathy.BioSpaceBayer Completes Acquisition of Perfuse TherapeuticsBayer completed its acquisition of Perfuse Therapeutics, integrating the company fully. Bayer paid a $300 million upfront payment, with total potential value up to $2.45 billion including milestone payments. The deal secures PER-001, a Phase II drug for glaucoma and diabetic retinopathy.Business Wire BlogBayer Completes Acquisition of Perfuse TherapeuticsBayer completed its acquisition of Perfuse Therapeutics, integrating the company fully. Bayer paid an upfront $300 million, with total potential value up to $2.45 billion including milestones. The deal secures PER-001, a Phase II endothelin receptor antagonist for glaucoma and diabetic retinopathy.Labiotech.euTop biotech deals in May 2026May 2026 saw significant biotech M&A and licensing activity, with Angelini Pharma acquiring Catalyst Pharmaceuticals for $4.1 billion, Bayer buying Perfuse Therapeutics for $2.45 billion, and UCB purchasing Candid Therapeutics for $2.2 billion. Eli Lilly made four acquisitions totaling up to $3.8 billion (Curevo, LimmaTech Biologics, Vaccine Company, Engage Bio), while Bristol Myers Squibb entered a landmark $15.2 billion licensing deal with Hengrui Pharma for 13 early-stage oncology, hematology, and immunology programs.